DOCSLIB.ORG

Complaint 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Complaint 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 2 3 4 IN THE CIRCUIT COURT OF THE STATE OF OREGON 5 FOR THE COUNTY OF MULTNOMAH 6 STATE OF OREGON, ex rel. ELLEN F. ROSENBLUM, Attorney General for the No. 19CV22185 7 State of Oregon, COMPLAINT 8 Plaintiff, Declaratory relief; Intentional fraudulent conveyance; 9 vs. Constructive fraudulent conveyance 10 RICHARD S. SACKLER, an individual; JONATHAN D. SACKLER, an individual; Not Subject to Mandatory 11 MORTIMER D.A. SACKLER, an individual; Arbitration KATHE A. SACKLER, an individual; ILENE 12 SACKLER LEFCOURT, an individual; Filing fee not collectible pursuant DAVID A. SACKLER, an individual; to ORS 21.259 13 BEVERLY SACKLER, an individual; THERESA SACKLER, an individual; DEMAND FOR JURY TRIAL 14 PURDUE PHARMA L.P., a Delaware limited partnership; and PURDUE PHARMA INC., a 15 New York corporation, 16 Defendants. 17 Plaintiff, for its complaint against defendants, alleges as follows: 18 INTRODUCTION 19 1. 20 Defendants Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe 21 A. Sackler, Ilene Sackler Lefcourt, David A. Sackler, Beverly Sackler, and Theresa Sackler 22 (the “Sacklers”) stand atop the “Sackler Pharmaceutical Enterprise,” a worldwide network of 23 pharmaceutical businesses, holding companies, and tax shelters, wholly owned by the 24 Sacklers and their families. The Sackler Pharmaceutical Enterprise is dedicated to 25 manufacturing, marketing, and promoting deadly opioid narcotics and hiding the profits. The 26 Page 1 - COMPLAINT MARKOWITZ HERBOLD PC SUITE 3000 PACWEST CENTER 1211 SW FIFTH AVENUE PORTLAND, OREGON 97204-3730 (503) 295-3085 Fax: (503) 323-9105 1 Sacklers exert complete and total control over all the entities in the Sackler Pharmaceutical 2 Enterprise. 3 2. 4 Together with their families, the Sacklers own 100 percent of defendants Purdue 5 Pharma L.P. and Purdue Pharma Inc. (“Purdue”), the makers of OxyContin. Purdue, at the 6 Sacklers’ direction, launched OxyContin in 1996. The drug kicked off a nationwide 7 epidemic. Every day, more than 115 Americans die after overdosing on opioids.1 In 2011, 8 the United States comprised 4.6% of the world’s population, but consumed 80% of the 9 world’s opioids.2 In 2015, more than 3 million opioid prescriptions were issued in Oregon, 10 enough for nearly every adult Oregonian to have a bottle of pills.3 By 2017, the crisis had 11 cost an estimated $1 trillion in the United States in lost wages, productivity, and tax revenue 12 and additional health care, social services, and criminal justice spending.4 13 3. 14 The Sacklers have known for nearly two decades that OxyContin is highly addictive, 15 dangerous, and deadly. By 2007, the damage wrought by OxyContin and Purdue’s 16 aggressive and unlawful marketing of the drug had exposed Purdue to catastrophic liability. 17 Fearing that Purdue would collapse under the weight of criminal and civil investigations and 18 more than 100 lawsuits, the Sacklers engaged in a concerted, planned effort to siphon billions 19 20 1 National Institute on Drug Abuse, Opioid Overdose Crisis (Mar. 2018), 21 https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis. 2 Donald Teater, The Psychological and Physical Side Effects of Pain Medications, 22 Nat’l Safety Council (2014), https://www.colorado.gov/pacific/sites/default/files/ Psycholigical%20and%20Physical%20Side%20Effects%20Teater%20NSC.pdf. 23 3 Geoff Mulvihill, Liz Essley Whyte, and Ben Wieder, Drugmakers Fought State 24 Opioid Limits Amid Crisis. THE BEND BULLETIN, (Sept. 18, 2016), https://www.bendbulletin.com/home/4668535-151/painkiller-problem-a-political-one-too. 25 4 Altarum Institute, Economic Toll of Opioid Crisis in U.S. Exceeded $1 Trillion Since 2001 (Feb. 13, 2018), https://altarum.org/about/news-and-events/economic-toll-of- 26 opioid-crisis-in-u-s-exceeded-1-trillion-since-2001. Page 2 - COMPLAINT MARKOWITZ HERBOLD PC SUITE 3000 PACWEST CENTER 1211 SW FIFTH AVENUE PORTLAND, OREGON 97204-3730 (503) 295-3085 Fax: (503) 323-9105 1 of dollars out of Purdue Pharma L.P. and transfer it to themselves and other entities in the 2 Sackler Pharmaceutical Enterprise. 3 4. 4 Over the following ten years, while Purdue continued to illegally market OxyContin, 5 the Sacklers milked $11 billion from Purdue Pharma L.P. In doing so, they starved the 6 company of cash, stifled its growth, and left it unable to satisfy its enormous legal liabilities 7 resulting from its continuous unlawful conduct. At every turn, the Sacklers have used Purdue 8 and all the entities in the Sackler Pharmaceutical Enterprise as their alter egos to avoid 9 personal liability and the jurisdiction of this and other courts nationwide. 10 5. 11 The State of Oregon, by and through Attorney General Ellen Rosenblum, brings this 12 action against the Sacklers to hold them personally accountable for their misconduct. 13 PARTIES, JURISDICTION, AND VENUE 14 6. 15 Ellen Rosenblum is the Attorney General of plaintiff, the State of Oregon. 16 7. 17 Defendant Purdue Pharma L.P. is a limited partnership organized under the laws of 18 Delaware with its principal place of business in Stamford, Connecticut. 19 8. 20 Purdue Pharma Inc. is a New York corporation with its principal place of business in 21 Stamford, Connecticut. 22 9. 23 Defendant Richard S. Sackler is a natural person residing in Travis County, Texas. 24 Richard Sackler served on the Board of Purdue Pharma Inc. from at least May 15, 2007 until 25 July 24, 2018. Until approximately 2003, Richard Sackler was the Chief Executive Officer 26 of Purdue. Page 3 - COMPLAINT MARKOWITZ HERBOLD PC SUITE 3000 PACWEST CENTER 1211 SW FIFTH AVENUE PORTLAND, OREGON 97204-3730 (503) 295-3085 Fax: (503) 323-9105 1 10. 2 Defendant Jonathan D. Sackler is a natural person residing in Fairfield County, 3 Connecticut. Jonathan Sackler served on the Board of Purdue Pharma Inc. from at least 4 May 15, 2007 until December 8, 2018. On and before May 31, 2007, Jonathan Sackler also 5 served as a Senior Vice President of Purdue Pharma Inc. and Purdue Pharma L.P. 6 11. 7 Defendant Mortimer D.A. Sackler is a natural person residing in New York County, 8 New York. Mortimer D.A. Sackler served on the Board of Purdue Pharma Inc. from at least 9 May 15, 2007 until January 16, 2019. On and before May 31, 2007, Mortimer D.A. Sackler 10 also served as a Vice President of Purdue Pharma Inc. and Purdue Pharma L.P. 11 12. 12 Defendant Kathe A. Sackler is a natural person residing in Fairfield County, 13 Connecticut. Kathe Sackler served on the Board of Purdue Pharma Inc. from at least 14 May 15, 2007 until September 27, 2018. On and before May 31, 2007, Kathe Sackler also 15 served as a Senior Vice President of Purdue Pharma Inc. and Purdue Pharma L.P. 16 13. 17 Defendant Ilene Sackler Lefcourt is a natural person residing in New York County, 18 New York. Ilene Sackler Lefcourt served on the Board of Purdue Pharma Inc. from at least 19 May 15, 2007 until October 9, 2018. 20 14. 21 Defendant Beverly Sackler is a natural person residing in Fairfield County, 22 Connecticut. Beverly Sackler served on the Board of Purdue Pharma Inc. from at least 23 May 15, 2007 until October 17, 2018. 24 25 26 Page 4 - COMPLAINT MARKOWITZ HERBOLD PC SUITE 3000 PACWEST CENTER 1211 SW FIFTH AVENUE PORTLAND, OREGON 97204-3730 (503) 295-3085 Fax: (503) 323-9105 1 15. 2 Defendant Theresa Sackler is a natural person residing in New York County, New 3 York. Theresa Sackler served on the Board of Purdue Pharma Inc. from at least May 15, 4 2007 until 2018. 5 16. 6 Defendant David Sackler is a natural person residing in New York. David Sackler 7 served on the Board of Purdue Pharma Inc. from July 19, 2012 until August 14, 2018. 8 17. 9 Subject matter jurisdiction is conferred on this Court by ORS 14.030. 10 18. 11 This Court has personal jurisdiction over Purdue pursuant to ORCP 4 A(4) because 12 Purdue is engaged in substantial and not isolated marketing, promotion, and sales of 13 pharmaceuticals in Oregon; ORCP 4 D(1) because the State suffered an injury in Oregon as a 14 result of Purdue’s fraudulent conveyances and, at the same time, Purdue carried out 15 solicitation activities within Oregon; and ORCP 4 E(4) because this action arises out of 16 pharmaceuticals received in Oregon from Purdue. 17 19. 18 This Court has personal jurisdiction over the Sacklers on the following bases: 19 a. Pursuant to ORCP 4 D(1) because the State suffered an injury in Oregon as a result of 20 the Sacklers’ fraudulent conveyances conducted outside of Oregon and, at the same 21 time, Purdue Pharma L.P. sales representatives conducted solicitation activities in 22 Oregon on behalf of the Sacklers. 23 b. Pursuant to ORCP 4 L because: i) Purdue Pharma L.P. engaged in illegal conduct in 24 Oregon giving the State claims against it and making the State a creditor of Purdue 25 Pharma L.P.; ii) as a result the State can exercise personal jurisdiction over Purdue 26 Pharma L.P.; iii) the Sacklers exercise complete dominion and control over Purdue Page 5 - COMPLAINT MARKOWITZ HERBOLD PC SUITE 3000 PACWEST CENTER 1211 SW FIFTH AVENUE PORTLAND, OREGON 97204-3730 (503) 295-3085 Fax: (503) 323-9105 1 Pharma L.P. such that Purdue Pharma L.P. is the agent of the Sacklers; and iv) where 2 a Court has personal jurisdiction over an agent, it has jurisdiction over its principal. 3 c. Pursuant to ORCP 4 L because: i) Purdue Pharma L.P.
Load more

Recommended publications
  • Sackler Complaint
    49D13-1905-PL-020498 Filed: 5/21/2019 9:44 AM Clerk Marion Superior Court, Civil Division 13 Marion County, Indiana IN THE CIRCUIT / SUPERIOR COURT FOR MARION COUNTY, INDIANA STATE OF INDIANA, Plaintiff, vs. RICHARD SACKLER, THERESA SACKLER, KATHE SACKLER, JONATHAN SACKLER, MORTIMER D.A. SACKLER, BEVERLY SACKLER, DAVID SACKLER, and ILENE SACKLER LEFCOURT, Defendants. COMPLAINT TABLE OF CONTENTS PRELIMINARY STATEMENT .................................................................................................... 1 PARTIES ...................................................................................................................................... 11 JURISDICTION AND VENUE ................................................................................................... 14 GENERAL ALLEGATIONS COMMON TO ALL COUNTS.................................................... 15 I. The Sackler Defendants, Through Purdue, Changed the Medical Consensus by Working Every Channel to Reach Prescribers and Indiana Patients. ................................................................................................................. 15 A. Purdue regularly met face-to-face with prescribers to promote its opioid drugs. ............................................................................................. 16 B. Purdue co-opted and exploited seemingly-independent channels to reach prescribers. ...................................................................................... 19 II. From Their Position of Control, the Sackler Defendants
    [Show full text]
  • AG Balderas Files Lawsuit Against Purdue Pharma's Sackler Family for Fueling Opioid Crisis
    For Immediate Release: September 10, 2019 Contact: Matt Baca (505) 270-748 AG Balderas Files Lawsuit Against Purdue Pharma's Sackler Family for Fueling Opioid Crisis Albuquerque, NM---Today, Attorney General Balderas took yet another step in holding accountable those responsible for New Mexico's opioid epidemic. In a lawsuit filed today, Attorney General Balderas brought action against the Sackler family for masterminding illegal and deceptive practices which caused millions of pills to come flooding into New Mexico. These eight members of the billionaire Sackler Family have owned and controlled Purdue for decades. Until recently, the Sacklers controlled a majority of the seats on the company's board and used the company to execute illegal and deadly schemes which helped lead New Mexico and the rest of the nation into the epidemic we are currently facing, all the while paying themselves billions. "The Sacklers are perhaps the most deadly drug dealers in the world. Because of their illegal actions, New Mexico faces some of the highest opioid related death numbers in the nation, and we have whole communities here in New Mexico which will never be the same again,” said Attorney General Balderas. "Today I am seeking to hold them accountable and to help end New Mexico's crisis and avoid more lives being lost." The Sacklers and Purdue designed their operations to pull the wool over the eyes of the public, state and federal regulators, and many doctors. They wrote the book on how to market narcotics directly to doctors and to the public-- convincing everyone through a decades-long misinformation campaign that pain was being under-treated, and that chronic, long-lasting pain of all sorts should be aggressively treated with their powerful opioid, oxycontin.
    [Show full text]
  • In Re Purdue Pharma LP, Et Al
    In re Purdue Pharma LP, et al. Joseph Hage Aaronson LLC Counsel to Raymond Sackler Family (“Side B”) Defense Presentation Part 2: Marketing April 26, 2021 1 Marketing 2 Board Members Did Not Personally Participate in Marketing • Board did not approve the content of any marketing material • Board relied on approval of all marketing material by (1) Medical, (2) Legal, and (3) Regulatory Affairs • Board relied on outside counsel’s audits and positive endorsement of Purdue’s Compliance Program • Board relied on OIG’s and IRO’s confirmations of compliance (2007-12) “In performing his duties, • Board relied on management’s confirmations marketing a director shall be entitled to rely on complied with state and federal laws (2007-18) information, opinions, reports or statements … prepared or presented by • Board relied on monitoring of sales calls by District Managers, … officers or employees of the corporation … whom Legal and Compliance the director believes to be reliable and competent in the matters presented ….” • Board Relied on compliance audits of key risk activities N.Y. Bus. Corp. Law §717 3 Board Knew Purdue Submitted All Marketing Materials to FDA § 314.81 Other postmarketing reports. (3) Other reporting—(i) Advertisements and promotional labeling. The applicant shall submit specimens of mailing pieces and any other labeling or advertising devised for promotion of the drug product at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product… https://www.govinfo.gov/content/pk g/CFR-1997-title21-vol5/xml/CFR- 1997-title21-vol5-sec314-81.xml 4 Board Knew FDA Issues Warning Letters for Non-Compliant Marketing Material a.
    [Show full text]
  • Affidavit of Jeffrey J. Pyle in Support of Emergency Motion to Terminate Impoundment
    COMMONWEALTH OF MASSACHUSETTS SUFFOLK, ss. SUPERIOR COURT No. 1884-cv-01808 (BLS2) ) COMMONWEALTH OF MASSACHUSETTS, ) ) Plaintiff, ) ) V ) ) PURDUE PHARMA L.P., PURDUE PHARMA INC., ) RICHARD SACKLER, THERESA SACKLER, ) KATHE SACKLER, JONATHAN SACKLER, ) MORTIMER D.A. SACKLER, BEVERLY SACKLER, ) DAVID SACKLER, ILENE SACKLER LEFCOURT, ) PETER BOER, PAULO COSTA, CECIL PICKETT, ) RALPH SNYDERMAN, JUDITH LEWENT, CRAIG ) LANDAU, JOHN STEWART, MARK TIMNEY, ANd ) RUSSELL J. GASDIA, ) ) Defendants ) ) AFFIDAVIT OF JEFFREY J. PYLE IN SUPPORT OF EMERGENCY MOTION TO TERMINATE IMPOUNDMENT I, Jeffrey J. Pyle, hereby depose and state as follows. l. I am counsel to non-parties Dow Jones & Company, Inc., publisher of The Wall Street Journal; Boston Globe Media Partners, LLC, publisher of S77T andThe Boston Globe; Reuters News and Media Inc., owner of the Reuters news agency; The New York Times Company, publisher of The New York Times; and Trustees of Boston University, through its radio station, WBUR (collectively, the "Media Consortium"). I make this affidavit pursuant to Rule 10 of the Uniform Rules of Impoundment Procedure in support of the Media Consortium's emergency motion to terminate impoundment of the First Amended Complaint and its accompanying exhibits. 099998\000 l 43\3 I I 3039 2. The members of the Media Consortium are moving to terminate impoundment in order to further the effons of their journalists to report on the above-captioned litigation. Each of the members of the Media Consortium has published one or more news articles concerning this litigation, and wishes to publish newsworthy information concerning the information contained in the Commonwealth's First Amended Complaint and the exhibits thereto.
    [Show full text]
  • Download Sackler Settlement Agreement
    SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (OIG-HHS) of the Department of Health and Human Services (HHS); the Defense Health Agency (DHA), acting on behalf of the TRICARE program; the Office of Personnel Management (OPM), which administers the Federal Employees Health Benefits Program (FEHBP); and the Indian Health Service (IHS) (collectively, the “United States”), and Dr. Richard Sackler, David Sackler, Mortimer D.A. Sackler, Kathe Sackler, and the Estate of Jonathan Sackler (collectively, the “Named Sacklers” and, with the United States, “the Parties”), through their authorized representatives.1 RECITALS A. The Named Sacklers are beneficiaries of trusts that indirectly own Purdue Pharma, L.P. (“Purdue”). B. Purdue is a Delaware Limited Partnership that is headquartered in Stamford, Connecticut. C. At all relevant times, Purdue, directly or through its subsidiaries, manufactured, marketed, and sold pharmaceutical products in the United States, including OxyContin. OxyContin is a branded, extended-release oxycodone tablet. Oxycodone is an opioid agonist 1.5 times more powerful than morphine with a high potential for addiction, abuse, and misuse. OxyContin is approved by HHS’s Food and Drug Administration (FDA) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which 1 To the extent the term ‘Named Sacklers’ appears in Recital A, Recital E, and the second sentence of Recital F, in those instances the term includes Jonathan Sackler, rather than the Estate of Jonathan Sackler.
    [Show full text]
  • F/K/A PURDUE PRODUCTS LP), JONATHAN D. SACKLER, "Division"
    CONSUMERPROTECTION DIVISION, IN THE CONSUMER OFFICE OF THE ATTORNEY GENERAL 200 St. Paul Place, 16th Floor PROTECTION DIVISION Baltimore, Maryland 21202, OF THE Proponent, OFFICE OF THE V. ATTORNEY GENERAL PURDUE PHARMA, L.P., THE PURDUE FREDERICK COMPANY, INC., PURDUEPHARMA INC., PURDUE PHARMACEUTICAL CPD Case No: 311366 PRODUCTS L.P., AVRIOHEALTH LIMITED PARTNERSHIP OAH Case No.: (f/k/a PURDUE PRODUCTS L.P.), RHODES PHARMACEUTICALS L.P, RICHARD S. SACKLER, JONATHAND. SACKLER, MORTIMER D.A. SACKLER, KATHE A. SACKLER, ILENE SACKLER LEFCOURT, THERESA SACKLER, and DAVID A. SACKLER, Respondents. AMENDEDSTATEMENT OF CHARGES The Consumer Protection Division of the Office of the Attorney General of Maryland (the "Division") hereby institutes this proceeding on behalfof the State of Maryland to enjoin Purdue Pharma, L.P., The Purdue Frederick Company, Inc., Purdue PharmaInc., Purdue Phannaceutical Products L.P., Avrio Health Limited Partnership (f/k/a Purdue Products L.P.), Rhodes Pharmaceuticals L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Theresa Sackler, and David A. Sackler (collectively, "Respondents") from engaging in unfair and deceptive trade practices and to obtain relief for consumersvictimized by Respondents' unfair and deceptive trade practices. -1- For decades, Respondents have repeatedly engaged in unfair, abusive, and deceptive trade practices in violation ofthe Maryland Consumer Protection Act, Md. Code Ann. §§ 13-101 etseq., by marketing and selling opioids - which comprise a dangerous, highly addictive, and oflten lethal class ofnatural, synthetic, and semi-synthetic painkillers - for conditions for whichthey are neither safe nor effective and which they, in fact, often exacerbate. Respondents disseminated to Maryland prescribers, consumers, and others, false and misleading information concerning the purported safety and efficacy ofopioid use for the treatment of chronic pain.
    [Show full text]
  • PURDUE PHARMA LP, Et Al., Debtors.1 Chapter 11 Case No. 19
    19-23649-rdd Doc 2488 Filed 03/15/21 Entered 03/15/21 23:56:19 Main Document Pg 1 of 213 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re: Chapter 11 PURDUE PHARMA L.P., et al., Case No. 19-23649 (RDD) Debtors.1 (Jointly Administered) DISCLOSURE STATEMENT FOR CHAPTER 11 PLAN FOR PURDUE PHARMA L.P. AND ITS AFFILIATED DEBTORS THIS IS NOT A SOLICITATION OF AN ACCEPTANCE OR REJECTION OF THE PLAN. ACCEPTANCES OR REJECTIONS MAY NOT BE SOLICITED UNTIL THIS DISCLOSURE STATEMENT HAS BEEN APPROVED BY THE BANKRUPTCY COURT. THIS DISCLOSURE STATEMENT IS BEING SUBMITTED FOR APPROVAL BUT HAS NOT BEEN APPROVED BY THE BANKRUPTCY COURT. THE INFORMATION IN THIS DISCLOSURE STATEMENT IS SUBJECT TO CHANGE. THIS DISCLOSURE STATEMENT IS NOT AN OFFER TO SELL ANY SECURITIES AND IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES. 1 The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P.
    [Show full text]
  • Suffolk County Clerk 09/13/2019 03:56 Pm Index No
    FILED: SUFFOLK COUNTY CLERK 09/13/2019 03:56 PM INDEX NO. 400000/2017 NYSCEF DOC. NO. 1582 RECEIVED NYSCEF: 09/13/2019 SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF SUFFOLK Index No.: 4000000/2017 IN RE OPIOID LITIGATION Part 48 Hon. Jerry Garguilo SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF SUFFOLK THE PEOPLE OF THE STATE OF NEW YORK, by Letitia James, Attorney General of the State of Index No.: 4000016/2018 New York, Part 48 Hon. Jerry Garguilo Plaintiff, -against- LETTER ROGATORY PURDUE PHARMA L.P., et al., Defendants. REQUEST FOR INTERNATIONAL JUDICIAL ASSISTANCE (LETTER ROGATORY) TO OBTAIN DISCOVERY FROM BANELA CORPORATION IN THE BRITISH VIRGIN ISLANDS The Supreme Court of the State of New York, County of Suffolk, Commercial Division, presents its compliments to the appropriate judicial authority having jurisdiction over civil claims sitting within the British Virgin Islands, and respectfully requests international judicial assistance to obtain evidence to be used in the above-captioned civil action pending before this Court. This Court requests the assistance described herein as necessary in the interests of justice. This request is made pursuant to, and in conformity with, the Hague Convention of 18 March 1970 on the Taking of Evidence Abroad in Civil or Commercial Matters, to which both the United States and the United Kingdom, including the British Virgin Islands, are a party. The Court considers that the evidence sought is directly relevant to the issues in dispute and is not within the meaning of the British Virgin Islands Reservations and Declarations regarding Article 23 of the Hague Evidence Convention.
    [Show full text]
  • Exhibits to Affidavit of Sydenham B. Alexander Iii
    COMMONWEALTH OF MASSACHUSETTS SUFFOLK, ss. SUPERIOR COURT C.A. No. 1884-cv-01808 (BLS2) ) COMMONWEALTH OF MASSACHUSETTS, ) ) V. ) ) PURDUE PHARMA L.P ., PURDUE PHARMA INC., ) RICHARD SACI<LER, THERESA SACI<LER, ) KATHE SACKLER, JONATHAN SACI<LER, ) MORTIMER D.A. SACKLER, BEYERLY SACKLER, ) DAVID SACKLER, ILENE SACKLER LEFCOURT, ) PETER BOER, PAULO COSTA, CECIL PICKETT, ) RALPH SNYDERMAN, JUDITH LEWENT, CRAIG ) LANDAU, JOHN STEWART, MARK TIMNEY, ) and RUSSELL J. GASDIA ) _____ _ _________ __) EXHIBITS TO AFFIDAVIT OF SYDENHAM B. ALEXANDER III ACCOMPANYING THE COMMONWEALTH'S OPPOSITION TO THE DIRECTOR DEFENDANTS' MOTION TO DISMISS THE FIRST AMENDED COMPLAINT PURSUANT TO MASSACHUSETTS RULE OF CIVIL PROCEDURE 12(b)(2) CONTAINS DOCUMENTS PRODUCED BY PURDUE PHARMA L.P. - MAY BE SUBJECT TO A MOTION TO IMPOUND BY PURDUE CERTIFICATE OF SERVICE I, Sydenham B. Alexander III, Assistant Attorney General, hereby certify that I have this day, June 19, 2019, served the foregoing document upon all parties by email to: Counsel for Defendants Purdue Pharma Counsel for Defendants Craig Landau, John L.P. and Purdue Pharma Inc. Stewart, and Mark Timney Timothy C. Blank, BBO # 548670 James R. Carroll, BBO # 554426 Jon E. Olsson, BBO # 698783 Maya P. Florence, BBO # 661628 Sarah Magen SKADDEN, ARPS, SLATE MEAGHER & Debra O' Gorman FLOM LLP DECHERT LLP 500 Boylston Street One International Place, 40th Floor Boston, Massachusetts 02116 100 Oliver Street [email protected] Boston, MA 02110-2605 [email protected] [email protected] [email protected] sarah. [email protected] Counsel for Defendant Russell J Gasdia debra.o'[email protected] Juliet A. Davison, BBQ # 562289 DAVISON LAW, LLC 280 Summer St., 5th Floor Counsel for Defendants Richard Saclder, Boston, MA 02210 Theresa Sack/er, Kathe Sack/er, Jonathan [email protected] Sack/er, Mortimer D.A.
    [Show full text]
  • Report and Recommendations Concerning the Relationship of the Sackler Family and Purdue Pharma with Tufts University
    TUFTS UNIVERSITY Report and Recommendations Concerning the Relationship of the Sackler Family and Purdue Pharma with Tufts University Yurko, Salvesen & Remz, P.C. One Washington Mall Boston, Massachusetts 02108 December 5, 2019 Table of Contents Pages Executive Summary 1 I. Background of Investigation 4 II. History of the Relationship of Tufts with the Sackler Family and Purdue Pharma 6 A. The Sackler Family 6 B. Purdue Pharma 9 III. The Pain Research, Education and Policy Program 11 IV. Center for the Study of Drug Development 15 V. Attempts to Influence or Actual Influence of Programs or Research at Tufts by Purdue or the Sackler Family 17 A. Direct Influence 18 B. Indirect Influence 21 C. Appearance of Influence 24 VI. Compliance with Tufts Policies 29 VII. Recommendations 30 Executive Summary There is no real dispute that there is an opioid crisis in the U.S., resulting is countless deaths, scores of people who remain addicted, wrecked lives, broken families and wounded communities. Still, there is some disagreement as to the dominant cause: pharmaceutical companies that illegally market their products, illegal drug pushers, drug wholesalers inattentive to red flags of questionable orders, willfully blind or unscrupulous prescribers, or inept and timid regulators. Some would say, “all of the above.” As the crisis unfolded and worsened, victims and regulators appropriately sought to assess blame and seek accountability. Inevitably, the focus was on the pharmaceutical companies that sold opioids, including (but not exclusively) Purdue Pharma (“Purdue”). No doubt this is because Purdue aggressively marketed OxyContin, in some instances illegally, seemingly oblivious to the consequences.
    [Show full text]
  • In the United States District Court for the District of Colorado
    Case 1:19-cv-02884 Document 2 Filed 10/09/19 USDC Colorado Page 1 of 186 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Civil Action 1:19-cv-02884 CITY OF GREELEY, Plaintiff, v. RICHARD S. SACKLER, JONATHAN D. SACKLER, MORTIMER D.A. SACKLER, KATHE A. SACKLER, ILENE SACKLER LEFCOURT, BEVERLY SACKLER, THERESA SACKLER, DAVID A. SACKLER, TRUST FOR THE BENEFIT OF MEMBERS OF THE RAYMOND SACKLER FAMILY, RHODES PHARMACEUTICALS L.P., RHODES TECHNOLOGIES INC., RHODES PHARMACEUTICALS INC., RHODES TECHNOLOGIES, ENDO HEALTH SOLUTIONS INC., ENDO PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICALS, INC., JOHNSON & JOHNSON, TEVA PHARMACEUTICALS INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, INC., CEPHALON, INC., ALLERGAN PLC f/k/a ACTAVIS PLC, ALLERGAN FINANCE, LLC f/k/a ACTAVIS, INC. f/k/a WATSON PHARMACEUTICALS, INC., WATSON LABORATORIES, INC., ACTAVIS LLC, ACTAVIS PHARMA, INC. f/k/a WATSON PHARMA, INC, MALLINCKRODT PLC, MALLINCKRODT, LLC, SPECGX LLC, PAR PHARMACEUTICAL COMPANIES, INC., PAR PHARMACEUTICAL, INC., MYLAN PHARMACEUTICALS, INC., AMNEAL PHARMACEUTICALS, LLC, AMNEAL PHARMACEUTICALS, INC., IMPAX GENERICS, IMPAX LABORATORIES, INC., KVK-TECH, INC., Case 1:19-cv-02884 Document 2 Filed 10/09/19 USDC Colorado Page 2 of 186 SANDOZ, INC., CARDINAL HEALTH, INC., MCKESSON CORPORATION, AMERISOURCEBERGEN DRUG CORPORATION, WALGREENS BOOTS ALLIANCE INC. a/k/a WALGREEN CO, WALMART, INC., SMITH’S FOOD & DRUG CENTERS, INC. d/b/a PEYTON’S PHOENIX, and JOHN AND JANE DOES 1 THROUGH 100, INCLUSIVE, Defendants. COMPLAINT Case 1:19-cv-02884 Document 2 Filed 10/09/19 USDC Colorado Page 3 of 186 TABLE OF CONTENTS I. INTRODUCTION ................................................................................................ 1 II. PARTIES ............................................................................................................ 8 III.
    [Show full text]
  • Gerard Uzzi, Esq. Alexander B. Lees, Esq. MILBANK LLP 55 Hudson Yards New York, New York 10001 Telephone
    19-23649-rdd Doc 1833 Filed 10/22/20 Entered 10/22/20 01:32:09 Main Document Pg 1 of 90 Gerard Uzzi, Esq. Jasmine Ball, Esq. Alexander B. Lees, Esq. Maura Kathleen Monaghan, Esq. MILBANK LLP Jeffrey J. Rosen, Esq. 55 Hudson Yards DEBEVOISE & PLIMPTON LLP New York, New York 10001 919 Third Ave. Telephone: (212) 530-5000 New York, NY 10022 Facsimile: (212) 530-5219 Telephone: (212) 909-6000 Facsimile: (212) 909-6836 Gregory P. Joseph, Esq. Mara Leventhal, Esq. Counsel for the Mortimer Sackler Family JOSEPH HAGE AARONSON LLC 485 Lexington Avenue, 30th Floor New York, New York 10017 Telephone: (212) 407-1200 Facsimile: (212) 407-1280 Counsel for the Raymond Sackler Family UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re: Chapter 11 PURDUE PHARMA L.P., et al., Case No. 19-23649 (RDD) Debtors.1 (Jointly Administered) NOTICE OF MOTION TO CONFIRM THAT PAYMENT BY THE SACKLER FAMILIES UNDER SETTLEMENT WITH THE UNITED STATES DEPARTMENT OF JUSTICE IS NOT PROHIBITED BY THIS COURT PLEASE TAKE NOTICE that on October 21, 2020, the Raymond Sackler family and 1 The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P.
    [Show full text]